996 / 1084
The accurate classification of MSI-GC may become clinically relevant for two reasons:
(1) MSI-GCs may not require
any standard adjuvant (radio-)chemotherapy
in a
curative setting;
(2) MSI-GCs express the immune checkpoint molecules PD-L1 and PD-1 and
may
be considered suitable for the treatment with immune checkpoint inhibitors
in
the palliative setting
03/28/2017